v3.25.0.1
Licensing Agreements and Deferred Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2021
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2020
Collaboration Agreement              
Revenue       $ 63,723 $ 58,443 $ 51,494  
Total deferred revenue:              
Deferred revenue, beginning balance       14,390      
Amounts recognized into revenue       (262)      
Deferred revenue, ending balance       14,128 14,390    
Incept              
Collaboration Agreement              
Royalties paid       1,834 1,713 1,466  
License Agreement | AffaMed              
Collaboration Agreement              
Revenue       262 $ 573 $ 1,037  
Transaction price allocated to performance obligations partially unsatisfied       128      
Amount of non-refundable upfront payments received             $ 12,000
Additional payments to be received upon the achievement of certain development and commercial milestones       87,000      
Milestone payment received $ 1,000   $ 1,000        
Clinical support payment received   $ 2,000          
Transaction price       16,000      
Potential regulatory, development and commercial milestone payments excluded from transaction price       $ 87,000      
License Agreement | AffaMed | Minimum              
Collaboration Agreement              
Remaining performance obligation, expected timing of satisfaction, period       7 years      
License Agreement | AffaMed | Maximum              
Collaboration Agreement              
Remaining performance obligation, expected timing of satisfaction, period       8 years